Janthur WD, Cantoni N, Mamot C. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci. 2012;13(12):16020–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FitzGerald DJ, et al. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Can Res. 2011;71(20):6300–9.

Article  CAS  Google Scholar 

Abdollahpour-Alitappeh M, et al. Antibody–drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234(5):5628–42.

Article  CAS  PubMed  Google Scholar 

Abdollahpour-Alitappeh M, et al. A developed antibody–drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line. Artificial cells, nanomedicine, and biotechnology. 2018;46(sup2):1–8.

Article  CAS  PubMed  Google Scholar 

Blythman HE, et al. Immunotoxins: Hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells. Nature. 1981;290(5802):145–6.

Article  CAS  PubMed  Google Scholar 

Jansen FK, et al. Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev. 1982;62:185–216.

Article  CAS  PubMed  Google Scholar 

Abdollahpour-Alitappeh M, et al. Monomethyl auristatin E, a potent cytotoxic payload for development of antibody-drug conjugates against breast cancer. Novelty in Biomed. 2017;5(3):98–103.

CAS  Google Scholar 

Abdollahpour-Alitappeh M, et al. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. J Cell Physiol. 2019;234(3):2693–704.

Article  CAS  PubMed  Google Scholar 

Abdollahpour-Alitappeh M, Razavi-Vakhshourpour S, Abolhassani M. Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker. Biotechnol Appl Biochem. 2018;65(6):841–7.

Article  CAS  PubMed  Google Scholar 

Descotes J. Immunotoxicity of monoclonal antibodies. MAbs. 2009;1(2):104–11.

Article  PubMed  PubMed Central  Google Scholar 

Becker N, Benhar I. Antibody-based immunotoxins for the treatment of cancer. Antibodies. 2012;1(1):39–69.

Article  CAS  Google Scholar 

Akbari B, et al. Immunotoxins in cancer therapy: Review and update. Int Rev Immunol. 2017;36(4):207–19.

Article  CAS  PubMed  Google Scholar 

Pastan I, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6(7):559–65.

Article  CAS  PubMed  Google Scholar 

Antignani A, FitzGerald D. Immunotoxins: the role of the toxin. Toxins. 2013;5(8):1486–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruins WS, et al. Targeted therapy with immunoconjugates for multiple myeloma. Front Immunol. 2020;11: 531045.

Article  Google Scholar 

Srivastava S, Luqman S. Immune-O-Toxins as the magic bullet for therapeutic purposes. Biomed Res Therapy. 2015;2:1–15.

Article  Google Scholar 

Khirehgesh MR, et al. Immunotoxins and nanobody-based immunotoxins: Review and update. J Drug Target. 2021;29(8):848–62.

Article  CAS  PubMed  Google Scholar 

Dieffenbach M, Pastan I. Mechanisms of resistance to immunotoxins containing pseudomonas exotoxin a in cancer therapy. Biomolecules. 2020;10(7):979.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munir I, et al. Immunotoxins, an advance tool for cancer treatment: review and update. Acta Poloniae Pharmaceutica-Drug Research. 2018;75(6):1267–77.

Article  CAS  Google Scholar 

Gehlsen, K.R., Protein Toxins as Antibody–Drug Conjugate (ADC) Payloads. 2019.

Fu Z, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Metrangolo V, Engelholm LH. Antibody-drug conjugates: the dynamic evolution from conventional to next-generation constructs. Cancers. 2024;16(2):447.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. 2023;15(3):713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khongorzul P, et al. Antibody–drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19.

Article  CAS  PubMed  Google Scholar 

Sassoon, I. and V. Blanc, Antibody–drug conjugate (ADC) clinical pipeline: a review. Antibody-drug conjugates, 2013: p. 1–27.

Darbandi A, et al. Antibody-antibiotic conjugates: a comprehensive review on their therapeutic potentials against bacterialinfections. J Clin Lab Anal. 2024;38:e25071.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gustafsson K, et al. Reversing clonal hematopoiesis and associated atherosclerotic disease by targeted antibody-drug-conjugate (ADC) conditioning and transplant. Blood. 2020;136:34–5.

Article  Google Scholar 

Han A, et al. Development of novel glucocorticoids for use in antibody–drug conjugates for the treatment of inflammatory diseases. J Med Chem. 2021;64(16):11958–71.

Article  CAS  PubMed  Google Scholar 

Yasunaga M, Manabe S, Matsumura Y. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Sci Rep. 2017;7(1):10735.

Article  PubMed  PubMed Central  Google Scholar 

Kreitman RJ. Immunotoxins. Expert Opin Pharmacother. 2000;1(6):1117–29.

Article  CAS  PubMed  Google Scholar 

Shafiee F, Aucoin MG, Jahanian-Najafabadi A. Targeted diphtheria toxin-based therapy: a review article. Front Microbiol. 2019;10: 465771.

Article  Google Scholar 

Potala S, Sahoo SK, Verma RS. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discovery Today. 2008;13(17–18):807–15.

Article  CAS  PubMed  Google Scholar 

Mousavi A, et al. In vivo tumor therapy with novel immunotoxin containing programmed cell death protein-1 and diphtheria toxin. Monoclon Antib Immunodiagn Immunother. 2021;40(3):113–7.

Article  CAS  PubMed  Google Scholar 

Havaei SM, Aucoin MG, Jahanian-Najafabadi A. Pseudomonas exotoxin-based immunotoxins: over three decades of efforts on targeting cancer cells with the toxin. Front Oncol. 2021;11: 781800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weldon JE, Pastan I. A guide to taming a toxin–recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011;278(23):4683–700.

Article